Roche’s RHHBY member company, Genentech, announced the FDA approval of TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke (AIS) in adults. As a ...

The FDA approval is based on a large multi-center ... In the first head-to-head trial comparing Xolair to multi-allergen oral immunotherapy (OIT), the study met its primary endpoint, showing ...

Additionally, preliminary results from Stage 3 of the OUtMATCH study provide early data on introducing allergenic foods into a patient’s diet after stopping Xolair. These findings were featured as ...

Last year, the US Food and Drug Administration (FDA) approved omalizumab— an injectable ... which compared omalizumab with “omalizumab-facilitated OIT” — use of OIT preceded by 8 weeks ...

Omalizumab (Xolair) injections outperformed oral immunotherapy (OIT) in increasing tolerance among children with multi-food allergy, largely because many patients couldn't tolerate OIT, findings from ...

First-ever head-to-head trial comparing Xolair and oral immunotherapy (OIT) Results were featured as late-breakers at the 2025 AAAAI Annual Meeting Xolair is the only US FDA-approved medicine to ...

In a new study, omalizumab, an injectable drug for food allergies, performed better than oral immunotherapy. A subsequent ...

19% in the OIT group in a head-to-head trial OIT had higher ... and Novartis AG NVS are co-developing and co-promoting Xolair. Last February, the FDA approved Xolair for reducing allergic ...

Xolair is the only US FDA-approved medicine to reduce allergic reactions in children and adults with ... Stage 2 of the OUtMATCH study showed Xolair was more effective with fewer side effects than ...

compared to 19% in the OIT group (odds ratio=2.6, p=0.031). After Stage 1 of the OUtMATCH study, which served as the basis for the FDA approval of Xolair for the treatment of food allergies ...